Renalytix AI plc
("RenalytixAI", the "Company")
Result of General Meeting
Renalytix AI plc (LSE : RENX ), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that at the general meeting of the Company held today the resolution to cancel the share premium account of the Company and to grant the Company the general authority to make market purchases of its own shares were passed. 99.99% (12,665,883 votes) of the votes were cast in favour of the resolution.
The Company is currently making the necessary court applications to enable it to proceed with the share buyback and will issue further updates at the appropriate time.
For further information, please contact:
Renalytix AI plc |
||
James McCullough, CEO |
Via Walbrook PR |
|
|
|
|
Stifel (Nominated Adviser & Broker) |
Tel: 020 7710 7600 |
|
Alex Price / Jonathan Senior / Ben Maddison |
|
|
|
|
|
N+1 Singer (Joint Broker) |
Tel: 020 7496 3000 |
|
Aubrey Powell / George Tzimas (Corporate Finance) |
|
|
Tom Salvesen (Corporate Broking) |
|
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or renalytix@walbrookpr.com
|
|
Paul McManus / Lianne Cawthorne |
Mob: 07980 541 893 / 07584 391 303 |
|